Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2022 - 2025)

Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue history spans 4 years, with the latest figure at $31.8 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $31.8 million; the TTM value through Dec 2025 reached $31.8 million, changed 0.0%, while the annual FY2025 figure was $31.8 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue reached $31.8 million in Q4 2025 per KNSA's latest filing, roughly flat from $31.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $31.8 million in Q4 2024 to a low of $261000.0 in Q4 2023.
  • Average Non-Current Deffered Revenue over 4 years is $17.6 million, with a median of $12.0 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 97.82% in 2023, then skyrocketed 12088.12% in 2024.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $12.0 million in 2022, then crashed by 97.82% to $261000.0 in 2023, then surged by 12088.12% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Non-Current Deffered Revenue are $31.8 million (Q4 2025), $31.8 million (Q3 2025), and $31.8 million (Q2 2025).